Department of Medical Genetics, University of Pecs, H-7624 Pecs, Szigeti 12, Hungary.
Genome Med. 2010 Sep 13;2(9):64. doi: 10.1186/gm185.
Candidate gene association studies, linkage studies and genome-wide association studies have highlighted the role of genetic factors in the development of ischemic stroke. This research started over a decade ago, and can be separated into three major periods of research. In the first wave classic susceptibility markers associated with other diseases (such as the Leiden mutation in Factor V and mutations in the prothrombin and 5,10-methylenetetrahydrofolate reductase (MTHFR) genes) were tested for their role in stroke. These first studies used just a couple of hundred samples or even less. The second and still ongoing period bridges the two other periods of research and has led to a rapid increase in the spectrum of functional variants of genes or genomic regions, discovered primarily in relation to other diseases, tested on larger stroke samples of clinically better stratified patients. Large numbers of these alleles were originally discovered by array-based genome-wide association studies. The third period of research involves the direct array screening of large samples; this approach represents significant progress for research in the field. Research into susceptibility genes for stroke has taught us that careful stratification of patients is critical, that susceptibility alleles are often shared between diseases, and that not all susceptibility factors that associate with clinical traits that are themselves risk factors for stroke (such as increase of triglycerides) necessarily represent susceptibility for stroke. Research so far has been mainly focused on large- and small-vessel associated stroke, and knowledge on other types of stroke, which represent much smaller population samples, is still very scarce. Although some susceptibility allele tests are on the palette of some direct-to-consumer companies, the clinical utility and clinical validity of these test results still do not support their use in clinical practice.
候选基因关联研究、连锁研究和全基因组关联研究强调了遗传因素在缺血性中风发展中的作用。这项研究始于十多年前,可以分为三个主要的研究阶段。在第一波研究中,经典的易感性标志物与其他疾病相关(如因子 V 的 Leiden 突变和凝血酶原及 5,10-亚甲基四氢叶酸还原酶(MTHFR)基因的突变),研究了它们在中风中的作用。这些最初的研究仅使用了几百个样本,甚至更少。第二波研究仍然在进行中,连接了前两个研究阶段,并导致与其他疾病相关的基因或基因组区域的功能变异体的范围迅速增加,这些变异体主要在更大的临床分层更好的中风样本中进行测试。最初,这些等位基因的大部分是通过基于阵列的全基因组关联研究发现的。第三波研究涉及对大量样本进行直接阵列筛选;这种方法代表了该领域研究的重大进展。中风易感性基因的研究使我们认识到,对患者进行仔细分层至关重要,易感性等位基因通常在疾病之间共享,与与中风自身风险因素(如甘油三酯增加)相关的临床特征相关的易感性因素不一定代表中风的易感性。迄今为止,研究主要集中在大血管和小血管相关的中风,而对其他类型的中风(代表更小的人群样本)的知识仍然非常匮乏。尽管一些易感性等位基因测试在一些直接面向消费者的公司的调色板中,但这些测试结果的临床实用性和临床有效性仍不支持将其用于临床实践。